Current Report Filing (8-k)
May 12 2022 - 04:23PM
Edgar (US Regulatory)
0001500198 false 0001500198 2022-05-12
2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of Earliest Event Reported):
May 12, 2022
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-54716 |
|
27-0863354 |
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
7599 Anagram Dr.,
Eden Prairie,
MN
55344
(Address of principal executive offices and zip code)
952-426-1383
(Registrant’s telephone number including area code)
(Registrant’s former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each
class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
Common Stock, par value $0.001 per share |
|
NMTC |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On May 12, 2022, NeuroOne Medical Technologies Corporation (the
“Company”) issued a press release announcing its financial results
for the quarter ended March 31, 2022. A copy of this press release
is furnished herewith as Exhibit 99.1 to this Current Report and is
incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Item 2.02, and Exhibit 99.1 hereto, shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any of the Company’s filings under the
Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any
incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
| |
NEUROONE MEDICAL TECHNOLOGIES
CORPORATION |
| Dated: May 12,
2022 |
|
|
| |
By: |
/s/ David Rosa |
| |
|
David Rosa |
| |
|
Chief Executive
Officer |
2
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Jan 2023 to Feb 2023
NeuroOne Medical Technol... (NASDAQ:NMTC)
Historical Stock Chart
From Feb 2022 to Feb 2023
